• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Protecting and Enhancing Revenue for Hospitals

Healthcare Revenue Cycle Management

  • Services
    • Reimbursement Services
    • Revenue Integrity
  • Insights
  • Blog
  • About
    • Core Values
    • Management Team
    • News
    • Careers
      • Current Openings
  • Contact
  • 877.4BESLER info@besler.com
  • Search
Mar 06

Summary of the $8.3 billion package to fund a response to coronavirus

Blog, Covid-19, News Michael Passanante

The following is a summary by Winning Strategies Washington on the $8.3 billion package to fund a response to coronavirus.

It provides $8.3 billion in all new funding for a robust response to this public health emergency. That includes $950 million for state and local health agencies to conduct vital public health activities, including surveillance, laboratory testing, infection control, contact tracing, and mitigation.

The following is a summary of its major provisions:

  • $61 million to the FDA to facilitate the development of medical countermeasures, devices, therapies, and vaccines to combat the coronavirus.
  • Allows $1 billion in loan subsidies to be made available to help small businesses, small agricultural cooperatives, small aquaculture producers, and non- profit organizations which have been impacted by financial losses as a result of the coronavirus outbreak.
  • $950 million for the CDC, of which $475 million must be allocated within 30 days, to support States, locals, territories, and tribes to conduct public health activities.
  • $300 million to replenish the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks.
  • Allows funding for CDC’s repatriation and quarantine efforts, laboratory testing, emergency operations, epidemiological investigations, public information, and surveillance and data analysis.
  • Allows reimbursement for State or local costs incurred for coronavirus preparedness and response activities between January 20 and the date of enactment of this emergency supplemental.
  • Allows funds to be used for construction or renovation of facilities to improve preparedness and response capabilities at the State and local level.
  • More than $2 billion for the Biomedical Advanced Research and Development Authority (BARDA) to support advanced research and development of vaccines, therapeutics, and diagnostics, prioritizing platform-based technologies with U.S.-based manufacturing.
  • $826 million for the National Institutes of Health to support basic research and development of vaccines, therapeutics, and diagnostics.
  • $300 million in contingency funding for procurement of vaccines, therapeutics, and diagnostics.
  • Requires that vaccines, therapeutics, and diagnostics developed using taxpayer funds must be available for purchase by the Federal government at a fair and reasonable price. Allows the Secretary of Health and Human Services to ensure that vaccines, therapeutics, and diagnostics developed using taxpayer funds be affordable in the commercial market.

Michael Passanante's avatar

About Michael Passanante

Michael Passanante is Vice President of Strategic Growth at BESLER.

sidebar

Blog Sidebar

Click here to follow our blog. Get the latest news and resources related to hospital reimbursement delivered to your inbox weekly.

Categories

  • Blog
  • Bundled Payments
  • Case Study
  • Compliance
  • Cost Report
  • Covid-19
  • DRG
  • HFMA Peer Review
  • IME
  • Infographic
  • News
  • Readmissions
  • Reimbursement
  • Revenue Cycle
  • Revenue Integrity
  • Special Report
  • The Hospital Finance Podcast®
  • Transfer DRG
  • Uncompensated Care
  • Webinar
  • White Paper

Subscribe to Podcast

Apple PodcastsGoogle PodcastsSpotifyAndroidRSS

Footer

Besler

Let’s Connect

609.514.1400 | 877.4BESLER
116 Village Blvd., Suite 200
Princeton, New Jersey 08540

BESLER’s Services

  • Reimbursement Services
    • Medicare Cost Report Reviews & Prep
    • DSH Reviews
    • S-10 Review
  • Revenue Integrity Services
    • Inpatient DRG Validation
    • Transfer DRG
    • IME Revenue Recovery

Follow our blog

Get weekly Medicare reimbursement insights

©2022 BESLER. BESLER is a service mark of Besler & Co., Inc. d/b/a BESLER | info@besler.com
Terms of Use / Privacy Policy / Website by Web Savvy Marketing
*HFMA staff and volunteers determined that Revenue Integrity Solutions including Transfer DRG Revenue Recovery Service, Inpatient DRG Validation and IME Revenue Recovery and Easy Work Papers have met certain criteria developed under the HFMA Peer Review Process. HFMA does not endorse or guarantee the use of this service.